The discovery of new innovative medicines is a priority for human health. It is in this context that the Medicinal Chemistry Research Group (CMFA) is pursuing its research activities.
Our team develops his expertise in the design and discovery of novel chemical tools and drugs to interrogate/target biological systems.
Over the past years, the group successfully designed and developed various series of inhibitors for anticancer immunotherapy and tumor metabolism using structure-based and fragment-based drug design approaches. The strategy was also applied to the discovery of new antibacterial agents.
More recently, our team has been interested in the development of molecules/peptides targeting protein-protein interactions using biophysical tools such as microscale thermophoresis (MST), NMR saturated transfer difference experiments or Differential Scanning Fluorimetry (DSF).
We are also studying pHLIP (pH-Low Insertion Peptides) that are peptides exploiting pH differences between healthy and diseased cells as a biomarker for targeting and delivering therapeutic to cells in acidic diseased tissues.